HIV infection and SLE: Their pathogenic relationship

Clinical and Experimental Rheumatology

Volumn 16, Issue 2, 1998, Pages 175-180

  Sekigawa, I ^a   Kaneko, H ^b   Hishikawa, T ^b   Hashimoto, H ^b   Hirose, S ^a   Kaneko, Y ^c   Maruyama, N ^d  

^a JUNTENDO UNIVERSITY SHIZUOKA HOSPITAL   (Japan)

^b JUNTENDO UNIVERSITY   (Japan)

^c AJINOMOTO CO INC   (Japan)

^d TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

Author keywords

HIV; HIV 1 gp120; Retrovirus; SLE; TNF

Indexed keywords

DISEASE ASSOCIATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0031778597     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. ZIEGLER J, STITES D: Hypothesis: AIDS is an autoimmune disease directed at the immune system and triggered by a lymphotropic retrovirus. Clin Immunol Immunopathol 1986; 41: 305-13.
2. KOPELMAN RG, ZOLLA-PAZNER S: Association of human immunodeficiency virus infection and autoimmune phenomena. Am J Med 1988; 84: 82-8.
3. BERMAN A, ESPINOZA LR, DIAZ JD, et al.: Rheumatic manifestations of human immunodeficiency virus infection. Am J Med 1988; 85: 59-64.
4. KAYE BR: Rheumatological manifestations of infection with human immunodeficiency virus (HIV). Ann Intern Med 1989; 111: 158-67.
5. ESPINOZA LR, AGUILAR JL, BERMAN A, GUTIERREZ F, VASEY FB, GERMAIN BF: Rheumatic manifestations associated with human immunodeficiency virus infection. Arthritis Rheum 1989; 32: 1615-22.
6. CALABRESE LH: The rheumatic manifestations of infections with the immunodeficiency virus. Semin Arthritis Rheum 1989; 18: 225-39.
7. DECLERK LS, COUTTENYE MM, DEBROE ME, STEVENTS WJ: Acquired immunodeficiency syndrome mimicking Sjögren's syndrome and systemic lupus erythematosus. Arthritis Rheum 1988; 31: 272-5.
8. MALATZKY-GOSHEN E, SHOENFELD Y: For debate: AIDS and autoimmunity. Autoimmunity 1989; 3: 201-12.
9. HOFFMANN GW, KION TA, GRANT MD: An idiotype network model of AIDS immunopathogenesis. Proc Natl Acad Sci USA 1991; 88: 3060-4.
10. CIMMINO MA, DE MARIA A, MOGGIANA G, PARISI M, QUERCI G, ACCARDO S: HIV infection in a male patient with systemic lupus erythematosus. Clin Exp Rheumatol 1996; 14: 317-20.
11. STRICKER RB, ABRAMS DL, CORASH LC, SHUMAN MA: Target platelet antigen in homosexual men with immune thrombocytopenia. N Engl J Med 1985; 313: 1375-80.
12. MCGINNISS MH, MACHER AM, ROOK AH, ALTER HJ: Red cell autoantibodies in patients with acquired immune deficiency syndrome. Transfusion 1986; 26: 405-9.
13. BLOOM EJ, ABRAMS DJ, RODGERS G: Lupus anticoagulant in the acquired immune deficiency syndrome. JAMA 1986; 256: 491-3.
14. SOLINGER AM, ADAMS LE. FRIEDMANKIEN AE, HESS EV: Acquired immune deficiency syndrome (AIDS) and autoimmunity-mutually exclusive entities ? J Clin Immunol 1988; 8: 32-42.
15. AMADORI A, CHIECO-BIANCHI L: B-Cell activation and HIV-1 infection: deeds and misdeeds. Immunol Today 1990; 11: 374-9
16. MEYAARD L, SCHUITEMAKER H, MIEDEMA F: T-cell dysfunction in HIV infection: anergy due to defective antigen-presenting cell function? Immunol Today 1993; 14: 161-4.
17. STTTES DP, CASAVANT CH, MCHUGH TM et al.: Flow cytometric analysis of lymphocyte phenotype in AIDS using monoclonal antibodies and simultaneous dual immunofluorescence. Clin Immunol Immunopathol 1986; 38: 161-77.
18. GELEZIUNAS R, BOUR S, WAINBERG MA: Cell surface down-modulation of CD4 after infection by HIV-1. FASEB J 1994; 8: 593-600.
19. KANEKO H, HISHIKAWA T, SEKIGAWA I, HASHIMOTO H, OKUMURA K, KANEKO Y: Role of tumor necrosis factor (TNF)-a in the induction of HIV-1 gp120-mediated CD4+ T cell anergy. Clin Exp Immunol 1997; 109: 41-7.
20. HISHIKAWA T, TOKANO Y, SEKIGAWA I et al.: HLA-DP+ T cells and deficient interleukin-2 production in patients with systemic lupus erythematosus. Clin Immunol Immunopathol 1990; 55: 285-96.
21. HORAK ID, POPOVIC M, HORAK EM et al.: No T-cell tyrosine protein kinase signaling or calcium mobilization after CD4 association with HIV-1 or HIV-1 gp120. Nature 1990; 348: 557-60.
22. DIAMOND DC, SLOCKMAN BP, GREGORY T, LASKY LA, GREANSTEIN JL, BURAKOFF SJ: Inhibition of CD4+ T cell function by the HIV envelope protein gp120. J Immunol 1988; 141: 3715-7.
23. SEKIGAWA I, HISHIKAWA T, KANEKO H et al.: FK506 can inhibit apoptotic cell death induced by the HIV-1 envelope glycoprotein gp120. AIDS 1994; 8: 1623-4.
24. SEKIGAWA I, KOSHINO K, HISHIKAWA T et al.: Inhibitory effect of the immunosuppressant FK506 on appoptotic cell death induced by HIV-1 gp120. J Clin Immunol 1995; 15: 312-7.
25. BANDA NK, BERNIER J, KURAHARA DK et al.: Crosslinking CD4 by human immunode-ficiency virus gp120 primes T cells for activation-induced apoptosis. J Exp Med 1992; 176: 1099-106.
26. BREEN EC, REZAI AR, NAKAJIMA K et al.: Infection with HTV is associated with elevated IL-6 levels. J Immunol 1990; 15: 480-4.
27. OYAIZU N, CHIRMULE N, OHNISHI Y, KALYANARAMAN VS, PAHWA S: Human immunodeficiency virus type 1 envelope gly-coproteins gp120 and gp160 induce interleukin-6 production in CD4+ T-cell clones. J Virol 1991; 65: 6277-82.
28. MACCHIA D, ALMERIGONA F, PARRONCHI P, RAVINA A, MAGGI E, ROMAGNANI S: Membrane tumor necrosis factor-α is involved in the polyclonal B-cell activation induced by HIV-infected human T cells. Nature 1993; 363: 464-6.
29. KARSTEN V, GORDON S, KIRN A, HERBEIN G: HIV-1 envelope glycoprotein gp120 down-modulates CD4 expression in primary human macrophages through induction of endogenous tumor necrosis factor-α. Immunology 1996; 88: 55-60.
30. 1ck with CD4 in human T lymphocytes. J Biol Chem 1991; 266: 11176-83.
31. HIVROZ C. MAZEROLLES F, SOULA M et al: Human immunodeficiency virus gp120 and derived peptides activate protein tyrosine kinase p56 in human CD4 T lymphocytes. Eur J Immunol 1993; 23: 600-7.
32. 1ck activation and TCR desensitization independent of TCR tyrosine phosphorylation. J Immunol 1994; 153: 2905-17.
33. ROSENSTEIN Y, BURAKOFF SJ, HERRMANN SH: HIV-gp120 can block CD4-class II MHC-mediated adhesion. J Immunol 1990; 144: 526-31.
34. FAITH A, O'HEHIR RE, MALKOVSKY M, LAMB JR: Analysis of the basis of resistance and susceptibility of CD4+ T cells to human immunodeficiency virus (HIV)-gp120 induced anergy. Immunology 1992; 76: 177-84.
35. FAITH A, YSSEL H, O'HEHIR RE, LAMB JR: Reversal of the inhibitory effects of HIV-gp120 on CD4+ T cells by stimulation through the CD28 pathway. Clin Exp Immunol 1996; 105: 225-30.
36. SCHOLS D, DE CLERCQ E: Human immunodeficiency virus type 1 gp120 induces anergy in human peripheral blood lymphocytes by inducing interleukin-10 production. J Virol 1996; 70: 4953-60.
37. ROMAGNANI S, DEL PRETE G, MANETTI R, et al.: Role of TH1/TH2 cytokines in HIV infection. Immunol Rev 1994; 140: 73-92.
38. MERONI L, TRABATTONI D, BALOTTA C, et al .: Evidence for type 2 cytokine production and lymphocyte activation in the early phases of HIV-1 infection. AIDS 1996; 10: 2330.
39. BARCELLINI W, RIZZARDI GP, BORGHI MO et al.: In vitro type-1 and type-2 cytokine production in systemic lupus erythematosus: lack of relationship with clinical disease activity. Lupus 1996; 5: 139-45.
40. COCCHI F, DEVICO AL, GARZINO-DEMO A, ARYA SK, GALLO RC, LUSSO P: Identification of RANTES, MIP-1, and MIP-1β as the major HIV-suppressive factors produced by CDS+ T cells. Science 1995; 270: 1811-5.
41. DENG H, LIU R, ELLMEIER W et al.: Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996; 381: 661-6.
42. DRAGIC T, LITWIN V, ALLAWAY GP et al.: HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996; 381: 667-73.
43. NEOH LP, AKIMOTO H, KANEKO H et al.: The production of β-chemokines induced by HIV-2 envelope glycoprotein. AIDS 1997; 11: 1062-3.
44. TAUB DD, TURCOVSKI-CORRALES SM, KEY ML, LONGO DL, MURPHY WJ: β-chemokines and T lymphocyte activation. I. β-chemokines costimulate human T lymphocyte activation in vitro. J Immunol 1996; 156: 2095-103.
45. MURPHY WJ, TIAN ZG, ASAIO et al.: Chemokines and T lymphocyte activation. II. Facilitation of human T cell trafficking in severe combined immunodeficiency mice. J Immunol 1996; 156: 2104-111.
46. BISSET LR, ROTHEN M, JOLLER-JEMELKA HI, DUBS RW, GROB PJ, OPRAVIL M: Change in circulating level of the chemokines macrophage inflammatory proteins 1α and 1β, RANTES, monocyte chemotactic protein-1 and interleukin-16 following treatment of severely immunodeficient HIV-infected individuals with indinavir. AIDS 1997; 11: 485-91.
47. KALDEN JR, GAY S. Retroviruses and autoimmune rheumatic disease. Clin Exp Immunol 1994; 98: 1-5.
48. HERRMANN M, HAGENHOFER M, KALDEN JR: Retrovirus and systemic lupus erythematosus. Immunol Rev 1996; 152: 145-56.
49. YOSHIKJ T, MELLORS RC, STRAND M et al.: The viral envelope glycoprotein of murine leukemia virus and the pathogenesis of immune complex glomerulonephritis of New Zealand mice. J Exp Med 1974; 140: 1011-27. 24
50. IZUI S, MCCONAHEY PJ, THEOFILOPONLOS AN et al.: Association of circulating retroviral gp70-anti-gp70 immune complexes with murine systemic lupus erythematosus. J Exp Med 1979; 149: 1099-116.
51. MELLORS RC, MELLORS JW: Antigen related to mammalian type-C RNA virus p30 proteins is located in renal glomeruli in human systemic lupus erythematosus. Proc Natl Acad Sci USA 1976; 73: 233-7.
52. RAYNOLDS JT, PANEM S: Characterization of antibody to C-type virus antigens isolated from immune complexes in kidneys of patients with systemic lupus erythematosus. Lab Invest 1981; 44: 410-9.
53. MAEDA S, YONEZAWA K, YACHI A: Serum antibody reacting with placental syncytiotrophoblast in sera of patients with autoimmune diseases: a possible relation to type C RNA retrovirus. Clin Exp Immunol 1985; 60: 645-53.
54. OKAMOTO T, TAMURA T. TAKANO T: Evidence in patients with systemic lupus erythematosus of the presence of antibodies against RNA-dependent DNA polymerase of 25 baboon endogenous virus. Clin Exp Immunol 1983; 54: 745-55.
55. QUERY CC, KEENE JD: A human autoimmune protein associated with UIRNA contains a region of homology that is cross-reactive with retroviral p30 gag antigen. Cell 1987; 51: 211-20.
56. TALAL N, GARRY RF, SCHUR PH et al.: A conserved idiotype and antibodies to retroviral proteins in systemic lupus erythematosus. J Clin Invest 1990; 85: 1866-71.
57. KOSHINO K, TOKANO T, HISHIKAWA I, SEKIGAWA I, TAKASAKI Y, HASHIMOTO H: Detection of antibodies to HIV-1 gp41and HLA class II antigen-derived peptides in SLE patients. Scand J Rheumatol 1995; 24: 288-92.
58. NAKAGAWA K, HARRISON LC: The potential roles of endogenous retroviruses in autoimmunity. Immunol Rev 1996; 152: 193-236.
59. BANKI K, MACEDA J, HURLEY E et al.: Human T-cell lymphotropic virus (HTLV)-related endogenous sequence, HRES-1, encodes a 28-kDa protein: a possible autoantigen for HTLV-1 gag-reactive autoantibodies. Proc Natl Acad Sci USA 1992; 89:1939-43.
60. BROOKES SM, PANDOLFINO YA, MITCHELL TJ et al.: The immune response to and expression of cross-reactive retroviral gag sequences in autoimmune disease. Br J Rheumatol 1992; 31: 735-42.
61. BLOMBERG J, NIVED O, PIPKORN R, BENGTSSON A, ERLINGE D, STURFELT G: Increased antiretroviral antibody reactivity in sera from a defined population of patients with systemic lupus erythematosus: correlation with autoantibodies and clinical manifestations. Arthritis Rheum 1994, 37: 57-66.
62. HERRMANN M, KALDEN JR: PCR and reverse dot hybridization for the detection of endogenous retroviral transcripts. J Virol Methods 1994; 46: 333-48.
63. HISHIKAWA T, OGASAWARA H, KANEKO H et al.: Detection of antibodies to recombinant gag protein derived from human endogenous retrovirus like sequence, clone 4-1, in autoimmune diseases. Viral Immunol 1997; 10: 137-47.
64. IMAMURA M, PHILLIPS PE, MELLORS RC: The occurrence and frequency of type C virus-like particles in placentas from patients with systemic lupus erythematosus and from normal subjects. Am J Pathol 1976; 83: 383-94.
65. DIRKSEN ER, LEVY JA: Virus-like particles in placentas from normal subjects and patients with systemic lupus erythematosus. J Natl Cancer Inst 1977; 59: 1187-92.
66. TAMURA N, SEKIGAWA I, HASHIMOTO H, YAMAMOTO N, KIRA S: Syncytial cell formation in vivo by type C retroviral particles in the systemic lupus erythematosus (SLE) lung. Clin Exp Immunol 1997; 107: 474-9.
67. GOLDING H, ROBEY FA, GATE III FT et al.: Identification of homologous regions in human immunodeficiency virus 1 gp41 and human MHC class II β 1 domain. I. Monoclonal antibodies against the gp41-derived peptide and patients' sera react with native HLA class II antigen, suggesting a role for autoimmunity in the pathogenesis of acquired immune deficiency syndrome. J Exp Med 1988; 167: 914-23.
68. GOLDING H, SHEARER GM, HILLMAN K et al.: Common epitope in human immunodeficiency virus (HIV) gp41 and HLA class II elicits immunosuppressive autoantibodies capable of contributing to immune dysfunction in HIV 1-infected individuals. J Clin Invest 1989; 83: 1430-5.
69. LEIB-MOSCH C, BRACK-WERNER R, WERNER T et al.: Endogenous retroviral elements in human DNA. Cancer Res 1993; 50: 5636s-42s.
70. REPASKE R, STOELE PE, O'NEILL RR, RABSON AB, MARTIN MA: Nucleotide sequence of a full-length human endogenous retroviral segment. J Virol 1985; 54: 764-72.
71. GARRY RF, FERMIN CD, HART DJ, ALEXANDER SS, DONEHOWER LA, LUO ZHANG H: Detection of a human intracisternal A-type retroviral particle antigenically related to HIV. Science 1990; 250: 1127-9.
72. FLESCHER E, DAUPHINEE MJ, FOSSUM D, LEDBETTER J, TALAL N: Signal transduction in Sjögren's syndrome T cells. Abnormalities associated with a newly described human A-type retrovirus. Arthritis Rheum 1992; 35: 1068-74.
73. GRIFFITHS DJ, VENABLES PJW, WEISS RA, BOYD MT: A novel exogenous retrovirus sequence identified in humans. J Virol 1997; 71: 2866-72.
74. WALLACE DJ and HAHN BH (Eds.): Dubois' Lupus Erythematosus. Maryland, Williams & Wilkins, 1996: 155-206.
75. CHAMS V, JONAULT T, FENONILLET E, GLUCKMAN JC, KLATZMANN D: Detection of anti-CD4 autoantibadies in the sera of HIV-infeated patients using recombinant soluble CD4 molocules. AIDS 1988; 2: 353-61.
76. KOWALSKI M, ARDMAN B, BASIRIPOUR L et al.: Antibodies to CD4 in individuals infected with human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1989; 86: 3346-50.
77. SEKIGAWA I, GROOPMAN JE, ALLAN JD et al.: Characterization of autoantibodies to the CD4 molecule in human immunodeficiency virus infection. Clin Immunol Immunopathol 1991; 58: 145-53
78. LENERT P, LENERT G, SENECAL JL: CD4-reactive antibodies in systemic lupus erythematosus. Hum Immunol 1996; 49: 38-48.
79. LENERT G, LENERT P: Human CD4-reactive antibodies from SLE patients induced reversible inhibition of polyclonal T lymphocyte proliferation. Hum Immunol 1996; 49: 113-21.
80. MOLINA JF, CITERA G, ROSLER D et al.: Coexistence of human immunodeficiency virus infection and systemic lupus erythematosus. J Rheumatol 1995; 22: 347-50.
81. BYRD VM, SERGENT JS: Suppression of systemic lupus erythematosus by the human immunodeficincy virus. J Rheumatol 1996; 23: 1295-6.
82. FOX R, ISENBERG DA: Human immunodeficiency virus infection in systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1168-72.
83. FONT J, VIDAL J, CERVERA R et al.: Lack of relationship between human immunodeficiency virus infection an systemic lupus erythematosus. Lupus 1995; 4: 47-9.
84. ALI M, TAYLOR GP, PITMAN RI, et al.: No evidence of antibody to human foamy virus in widespread human populations. AIDS Res Hum Retroviruses 1996; 12: 1473-83.